| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026 |
| 10 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease |
| 06 Aug 2026 |
8-K: Other Events
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week |
| 30 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of July 30, 2026 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability... |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Annexon, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 11, 2026. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, wi... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA |
| 17 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 14 Jan 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 STOPPING NEUROINFLAMMATION AT ITS SOURCE TH 44 ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 2026 Nasdaq: ANNX ©2025 Annexon, Inc. All rights reserved |
| 12 Jan 2026 |
8-K: Other Events
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 |
| 14 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
25,096,153 Shares of Common Stock, par value $0.001 per share |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA |
| 25 Jun 2025 |
8-K: Material Modification to Rights of Security Holders
This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT, dated as of June [•], 2025 (this “Amendment”), amends that certain COMMON STOCK PURCHASE WARRANT (the “Warrant”), dated as of July 11, 2022, by Annexon, Inc. (the “Company”) for the ... |
| 09 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Annexon, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 5, 2025. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, wit... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission |
| 03 Mar 2025 |
8-K: Results of Operations and Financial Condition
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License Application (BLA) Submission |
| 13 Jan 2025 |
8-K: Other Events
ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission |
| 10 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations |
Loading...